trending Market Intelligence /marketintelligence/en/news-insights/trending/rrDLN6tlLG8h8BGANjdaAA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Aerie Pharmaceuticals Inc. has completed its acquisition of Avizorex Pharma SL in an all-cash deal worth $10 million.

The Durham, N.C.-based company previously said the acquisition will expand its eye disease product portfolio.

Avizorex's therapy AVX-012 has shown positive results during a phase 2a clinical trial in patients with dry eye disease. The drug acts on the TRPM8 protein, which is believed to play a role in treating dry eye disease, a common condition that occurs when tears are not able to provide adequate lubrication for the eyes.

Aerie also acquired the rights to other compounds that target TRPM8 through the Avizorex deal.